| Abstract: |
Key Points: Question: Does estrogen receptor (ER)–targeted 16α-18F-fluoro-17β-estradiol (FES) positron emission tomography (PET) computed tomography (CT) perform as well as current standard-of-care imaging (SOC) for staging locally advanced breast cancer or evaluating suspected recurrence? Findings: In this diagnostic study of 124 patients with ER-positive breast cancer, there was no statistically significant difference between SOC and experimental FES PET/CT for detection of pathologically proven distant metastases or recurrences. Meaning: These findings suggest that FES PET/CT could be considered for staging or detection of recurrence in patients with ER-positive breast cancer. This diagnostic study assesses the detection rates for distant metastases in patients with estrogen receptor (ER)–positive breast cancer and recurrences in patients with ER-positive breast cancer using 16α-18F-fluoro-17β-estradiol positron emission tomography (PET) compared with standard-of-care imaging. Importance: There are insufficient data comparing 16α-18F-fluoro-17β-estradiol (FES) positron emission tomography (PET) computed tomography (CT) with standard-of-care imaging (SOC) for staging locally advanced breast cancer (LABC) or evaluating suspected recurrence. Objective: To determine the detection rate of FES PET/CT and SOC for distant metastases in patients with estrogen receptor (ER)-positive LABC and recurrences in patients with ER-positive BC and suspected recurrence. Design, Setting, and Participants: This diagnostic study was conducted as a single-center phase 2 trial, from January 2021 to September 2023. The study design provided 80% power to find a 20% detection rate difference. Participants included patients with ER-positive LABC (cohort 1) or suspected recurrence (cohort 2). Data were analyzed from September 2023 to February 2024. Exposure: Participants underwent both SOC imaging and experimental FES PET/CT. When there were suspicious lesions on imaging, 1 was biopsied for histopathological reference standard to confirm presence (true positive) or absence (false positive) of malignant neoplasm. Main Outcomes and Measures: The outcome of interest was the detection rate of FES PET CT vs SOC for distant metastases and recurrences. Results: A total of 124 patients were accrued, with 62 in cohort 1 (median [IQR] age, 52 [32-84] years) and 62 in cohort 2 (median [IQR] age, 66 [30-93] years). In cohort 1, of 14 true-positive findings, SOC imaging detected 12 and FES detected 11 (P >.99). In cohort 2, of 23 true-positive findings, SOC detected 16 and FES detected 18 (P =.77). In 30 patients with lobular histology, of 11 true-positive findings, SOC detected 5 and FES detected 9 (P =.29). There were 6 false-positive findings on SOC and 1 false-positive finding on FES PET/CT (P =.13). Conclusions and Relevance: In this diagnostic study with pathological findings as the reference standard, no difference was found between FES PET/CT and current SOC imaging for detecting distant metastases in patients with ER-positive LABC or recurrences in patients with ER-positive tumors and suspected recurrence. FES PET/CT could be considered for both clinical indications, which are not part of current Appropriate Use Criteria for FES PET. The findings regarding FES PET/CT in patients with lobular tumors, and for lower false positives than current SOC imaging, warrant further investigation. |
